Thursday, December 19, 2013
Publication and contact
analogs (staralogs) with improved selectivity toward analog-sensitive kinases
Staralogs could expand
approaches to study kinase function using analog-sensitive kinase variants.
Kinase variants with genetically engineered sensitivity to ATP analogs have
been used in functional studies, but in some cases the ATP analogs also
inhibit wild-type and unrelated kinases. In cultured cells, staralogs
inhibited analog-sensitive variants of EPH
receptor A4 (EPHA4),
dehydrogenase kinase 1
kinases but not their wild-type counterparts. Next steps include developing
staurosporine analogs and analog-sensitive kinases for use in animal studies.
Published online Dec. 19, 2013
Patented; licensing status
Lopez, M.S. et al. J.
Am. Chem. Soc.; published online Oct. 30, 2013;
Contact: Kevan M. Shokat, University of California, San
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]